Digital PNG artwork · delivered by email | Secure checkout · no physical shipping

How does AMPK activation work?

AMPK is a heterotrimeric serine/threonine kinase that acts as a cellular energy sensor. This page outlines its activation mechanism and summarises research findings from in vitro, animal, and human studies.

How does AMPK activation work?

AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase consisting of a catalytic α-subunit and regulatory β- and γ-subunits [8]. It functions as a cellular energy sensor and is activated by increases in the AMP:ATP ratio, which allows the γ-subunit to bind AMP and promote phosphorylation of the α-subunit by upstream kinases such as LKB1. Once active, AMPK phosphorylates downstream targets, including acetyl-CoA carboxylase (ACC), to inhibit anabolic processes and stimulate catabolic pathways that restore energy balance.

The work described here centres on the AMPK signalling pathway and its role in metabolic regulation across various cell types and model systems.

Research Studies

Astaxanthin and autophagy in granulosa cells from women with PMOS

A triple-blind, placebo-controlled pilot randomised trial investigated whether astaxanthin (AST) modulates autophagy-related signalling in granulosa cells (GCs) from women with polyendocrine metabolic ovarian syndrome (PMOS), formerly referred to as polycystic ovary syndrome (PCOS) [1]. Fifty women with PMOS-related anovulatory infertility received AST (12 mg/day) or placebo. The study evaluated autophagy markers and ovarian response. The findings suggest that AST influences autophagy in GCs, but the trial was a pilot and the authors noted that further research is needed to confirm these effects.

Oxidative eustress and AMPK/AKT activation in skeletal muscle cells

In C2C12 myoblasts and myotubes, exposure to redox-modulating stimuli associated with oxidative eustress—including hydrogen peroxide, nitric oxide donors, and angiotensin II—led to phosphorylation of AMPK and AKT, GLUT4 translocation, and increased glucose uptake [2]. This in vitro work indicates that moderate oxidation can activate AMPK signalling and promote glucose uptake in skeletal muscle cells.

Salsalate and AMPK dependency in renal epithelial cells

In cellular models of autosomal dominant polycystic kidney disease (ADPKD), targeted analysis of salicylate binding partners revealed a major dependency on AMPK [3]. Salsalate, an AMPK activator, had previously been shown to ameliorate disease progression in vivo to a similar extent as tolvaptan. The study identified multiple AMPK-dependent mechanisms, including effects on metabolic reprogramming, cell proliferation, and inflammation.

AMPK and macrophage crosstalk in diabetes

A review of the bidirectional interaction between AMPK signalling and macrophage function in diabetes mellitus reported that AMPK suppresses pro-inflammatory M1 responses by inhibiting NF-κB and JNK signalling, activating CREB/SIRT1 pathways, and promoting oxidative metabolism [4]. In adipose tissue, macrophages adopt a pro-inflammatory M1 phenotype in diabetes, secreting cytokines such as TNF-α, IL-6, and IL-1β that disrupt insulin signalling. AMPK activation appears to counter these effects, but the evidence is largely from preclinical models.

Bitter melon compounds and AMPK activation in myotonic dystrophy type 1

A screen of 26 bitter melon-derived compounds (BMCs) in C2C12 myotubes identified BMC-25 as a potent AMPK activator [5]. In a mouse model of myotonic dystrophy type 1 (DM1), treatment with BMC-25 ameliorated the skeletal muscle phenotype in a sex-specific manner. The study noted that DM1 is characterised by repression of the AMPK pathway, and targeting AMPK represents a potential therapeutic avenue.

Hepassocin and AMPK in liver senescence and regeneration

Hepassocin (HPS), a hepatokine with hepatoprotective functions, was reported to prevent age-related liver senescence and facilitate liver regeneration by activating AMPK [7]. This reference-only finding indicates a role for AMPK in hepatic aging and regenerative capacity, though the specific mechanisms were not detailed in the available evidence.

Pan-AMPK activator MK-8722 in human endothelial cells

In human endothelial cells, the pan-AMPK activator MK-8722 outperformed the AMPK activators SC4 and A-769662 in activating AMPK [8]. AMPK regulates endothelial homeostasis and is a target for pharmacological activators in endothelial dysfunction. The study compared the efficacy of these activators, but the full results were not available in the evidence block.

Palmitic acid and AMPK suppression in airway epithelial cells

In 16HBE airway epithelial cells, obesity-related palmitic acid exacerbated IL-13-induced mucus phenotype via AMPK suppression [9]. This reference-only finding suggests that AMPK suppression may link obesity to worsened childhood asthma outcomes, but the study was limited to in vitro models.

Exercise preconditioning and AMPK-ACC signalling in myocardial ischemia/reperfusion

In C57BL/6J mice, six weeks of treadmill exercise preconditioning activated AMPK-ACC signalling and attenuated myocardial ischemia/reperfusion-induced ferroptosis [10]. This reference-only finding indicates that exercise-induced AMPK activation may confer cardioprotection, but the evidence is from animal models.

TMZ plus 6-MP in recurrent glioblastoma

A clinical trial (NCT06279767) is evaluating the efficacy and safety of temozolomide (TMZ) plus 6-mercaptopurine (6-MP) in patients with recurrent glioblastoma [6]. While this trial does not directly investigate AMPK activation, it represents ongoing research into combination therapies for glioblastoma. The evidence block does not specify any AMPK-related outcomes for this trial.

If you are reading this for personal health reasons

The compounds and research materials discussed here are sold for laboratory research purposes only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp